MMV367   Click here for help

GtoPdb Ligand ID: 13673

Synonyms: GSK3772701 | GSK701 | MMV1582367
Antimalarial Ligand
Compound class: Synthetic organic
Comment: MMV367 is an antimalarial clinical candidate, selected from a new class of pyrrolidinamide-containing compounds identified from a phenotypic screen. The chemical structure was first disclosed during the 265th National Meeting of the American Chemical Society (Boston, 2018) [4] and is one of the structures claimed in patent WO2019145360A1 [2].

The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 8
Topological polar surface area 90.09
Molecular weight 411.43
XLogP 0.34
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=C(C=CC(=C1)F)[C@H]2CCN(C2)C(=O)C3=CC=C(C=C3)OC[C@@H](CN4N=CN=N4)O
Isomeric SMILES C1CN(C[C@H]1C2=CC=C(C=C2)F)C(=O)C3=CC=C(C=C3)OC[C@@H](CN4N=CN=N4)O
InChI InChI=1S/C21H22FN5O3/c22-18-5-1-15(2-6-18)17-9-10-26(11-17)21(29)16-3-7-20(8-4-16)30-13-19(28)12-27-24-14-23-25-27/h1-8,14,17,19,28H,9-13H2/t17-,19+/m0/s1
InChI Key RMWYAYFMEWWLSK-PKOBYXMFSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
MMV367 is in clinical development for the treatment of uncomplicated malaria. It has completed a first-in-human study to evaluate safety, tolerability, and pharmacokinetics in healthy volunteers (NCT05507970).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05507970 First-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV367 Phase 1 Interventional Medicines for Malaria Venture